Nanozora (ozoralizumab) vs Tofidence (tocilizumab-bavi)
Nanozora (ozoralizumab) vs Tofidence (tocilizumab-bavi)
Nanozora (ozoralizumab) is an investigational nanobody-based biologic agent that targets TNF-alpha, a key molecule involved in the inflammation process, and is being studied for the treatment of rheumatoid arthritis and potentially other inflammatory diseases. Tofidence (tocilizumab-bavi), on the other hand, is a biosimilar to tocilizumab, an FDA-approved monoclonal antibody that inhibits the interleukin-6 (IL-6) receptor, and is used for the treatment of moderate to severe rheumatoid arthritis, among other conditions. When deciding between Nanozora and Tofidence, a patient should consider the specific mechanism of action, the safety and efficacy data of each medication, and consult with their healthcare provider to determine which treatment aligns best with their individual medical history and disease profile.
Difference between Nanozora and Tofidence
| Metric | Nanozora (ozoralizumab) | Tofidence (tocilizumab-bavi) |
|---|---|---|
| Generic name | Ozoralizumab | Tocilizumab-bavi |
| Indications | Rheumatoid arthritis | Giant cell arteritis, Rheumatoid arthritis, Cytokine release syndrome |
| Mechanism of action | Anti-TNF nanobody | IL-6 receptor inhibitor |
| Brand names | Nanozora | Tofidence |
| Administrative route | Subcutaneous injection | Intravenous infusion, Subcutaneous injection |
| Side effects | Infections, Injection site reactions | Upper respiratory tract infections, Headache, Hypertension, Injection site reactions |
| Contraindications | Active infections, Hypersensitivity to the active substance | Active infections, Hypersensitivity to tocilizumab or excipients |
| Drug class | Biologic DMARD, TNF inhibitor | Biologic DMARD, IL-6 inhibitor |
| Manufacturer | Not widely available; limited information | Genentech (Roche) |
Efficacy
Efficacy of Nanozora (Ozoralizumab) in Rheumatoid Arthritis
Ozoralizumab, known under the brand name Nanozora, is an investigational monoclonal antibody designed for the treatment of rheumatoid arthritis (RA). While it is not yet widely approved, clinical trials have shown promising results regarding its efficacy. Ozoralizumab targets and neutralizes tumor necrosis factor-alpha (TNF-alpha), a cytokine that plays a significant role in the inflammatory processes of RA. By inhibiting TNF-alpha, Nanozora has demonstrated the potential to reduce the signs and symptoms of RA, improve physical function, and possibly slow the progression of joint damage.
In clinical studies, patients treated with Nanozora have shown significant improvements in the American College of Rheumatology (ACR) response criteria, which measure the reduction of RA symptoms. These improvements were observed at various doses, indicating a dose-dependent response. Additionally, some patients achieved clinical remission or low disease activity, suggesting that Nanozora may offer substantial benefits for individuals with moderate to severe RA.
Efficacy of Tofidence (Tocilizumab-bavi) in Rheumatoid Arthritis
Tocilizumab-bavi, sold under the brand name Tofidence, is a biosimilar to the original tocilizumab, which is an interleukin-6 (IL-6) receptor inhibitor used in the treatment of RA. The efficacy of Tofidence has been evaluated in clinical trials that compare it to the reference product, showing that it has similar efficacy in reducing the symptoms of RA. Tofidence works by blocking the action of IL-6, a cytokine that is involved in the inflammatory response associated with RA.
Clinical trials have demonstrated that Tofidence effectively reduces the signs and symptoms of RA, as measured by ACR response criteria. Patients receiving Tofidence have also reported improvements in physical function and quality of life. Furthermore, Tofidence has been shown to slow the progression of joint damage, which is a critical aspect of managing RA in the long term. The biosimilar nature of Tofidence ensures that it provides a similar efficacy profile to the original tocilizumab, making it a viable and potentially more cost-effective treatment option for patients with RA.
Regulatory Agency Approvals
Nanozora
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Tofidence
-
Food and Drug Administration (FDA), USA
Access Nanozora or Tofidence today
If Nanozora or Tofidence are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us